Press Detail

PRESS RELEASE

Biotest opens another plasma collection center in the US

- Biotest continues strengthening global plasma collection with a second plasma
  collection center in Jacksonville, North Caroline, US

Dreieich, February 9, 2015. Biotest announces that Biotest Pharmaceuticals Corporation (BPC), a 100% subsidiary of Biotest AG, Dreieich, has opened a new plasma collection center in the US. The state-of-the-art, 15,000 square foot facility located in Jacksonville, North Carolina, is BPC's second plasma center in Jacksonville, and officially opened its doors for business on February 3, 2015.

"We continue to expand our U.S. plasma collection operations to better serve the thousands of patients world-wide who rely on plasma based therapies" said Jordan Siegel, BPC's Chief Executive Officer.

The plasma donated at Biotest Plasma Centers is used to manufacture critical care therapies that treat life-threatening disorders in a variety of therapeutic areas, such as BPC's BIVIGAM^(R) [Immune Globulin Intravenous (Human), 10% Liquid] and Nabi-HB^(R) [Hepatitis B Immune Globulin (Human)].

Disclaimer

This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.

About Biotest

Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of rheumatoid arthritis and cancer of plasma cells, which are produced by recombinant technologies. Biotest has more than 2.100 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
e-mail: investor_relations@biotest.de
fax: +49 (0) 6103 801-347

Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover, München, Stuttgart